Several inflammatory cytokines play a role in the pathogenesis of eczema, and many of these cytokines require the activation of the JAK/STAT signaling pathway to play their parts. TYK2 is a member of the JAK kinase family, which plays a role in the signaling pathway of IL-12, IL-23, and type I IFNs. In the beginning and acute phase of the disease, IL-4 and IL-13 cytokines can activate B cells and cause antibody class switching for IgE. IgE secreted from plasma cells by binding to FcεRI on the surface of mast cells and basophils leads to the release of pro-inflammatory cytokines from these cells. IL-23 affects the differentiation and survival of Th17, which plays a vital role in inflammatory diseases because of the secretion of IL-17, IL-1, and TGFB cytokines. Due to the importance of TYK2 in inflammatory cytokines signaling, TYK2 inhibitors have been used in several inflammatory diseases such as Psoriasis, Lupus, Crohn's, Psoriatic arthritis, and Ulcerative colitis